DCF Advisers LLC Sells 500 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

DCF Advisers LLC reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,819 shares of the medical equipment provider’s stock after selling 500 shares during the quarter. Zimmer Biomet makes up about 1.2% of DCF Advisers LLC’s investment portfolio, making the stock its 26th largest holding. DCF Advisers LLC’s holdings in Zimmer Biomet were worth $2,410,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Stonebridge Financial Group LLC bought a new position in shares of Zimmer Biomet during the fourth quarter worth $25,000. Dunhill Financial LLC boosted its position in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares during the last quarter. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the third quarter worth $35,000. Kentucky Trust Co bought a new position in shares of Zimmer Biomet during the fourth quarter worth $39,000. Finally, OFI Invest Asset Management bought a new position in shares of Zimmer Biomet during the fourth quarter worth $40,000. 88.89% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.95% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ZBH shares. JMP Securities restated a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Royal Bank of Canada decreased their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Stifel Nicolaus upped their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Trading Down 1.1 %

ZBH stock opened at $111.72 on Friday. The company has a market capitalization of $22.24 billion, a PE ratio of 25.11, a P/E/G ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90. The firm’s 50-day moving average is $106.62 and its 200 day moving average is $106.96. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the business posted $2.20 EPS. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.86%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s payout ratio is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.